{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:15Z","timestamp":1793121495945,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"am","delay-in-days":440,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1053\/j.seminhematol.2023.06.003","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T01:51:03Z","timestamp":1688003463000},"page":"164-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical applications of circulating tumor DNA in indolent B-cell lymphomas"],"prefix":"10.1053","volume":"60","author":[{"given":"Rahul","family":"Lakhotia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1053\/j.seminhematol.2023.06.003_bib0001","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.06.003_bib0002","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for waldenstr\u00f6m's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.06.003_bib0003","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.06.003_bib0004","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-Cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.06.003_bib0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primer"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.06.003_bib0006","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.06.003_bib0007","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.06.003_bib0008","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"B\u00f6ttcher","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.06.003_bib0009","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.06.003_bib0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2023.06.003_bib0011","series-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","first-page":"437","author":"Hoster","year":"2016"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.06.003_bib0012","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.06.003_bib0013","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: The FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.06.003_bib0014","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"28","key":"10.1053\/j.seminhematol.2023.06.003_bib0015","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.06.003_bib0016","doi-asserted-by":"crossref","unstructured":"Distler A, lakhotia R, phelan JD, Pittaluga S. A prospective study of clonal evolution in follicular lymphoma: circulating tumor DNA correlates with overall tumor burden and fluctuates over time without therapy. Blood. 138 (Supplement 1):1328.","DOI":"10.1182\/blood-2021-151096"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.06.003_bib0017","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.06.003_bib0018","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2023.06.003_bib0019","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.clinbiochem.2015.03.015","article-title":"Digital PCR analysis of circulating nucleic acids","volume":"48","author":"Hudecova","year":"2015","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.06.003_bib0020","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/HS9.0000000000000347","article-title":"Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL network","volume":"4","author":"Drandi","year":"2020","journal-title":"HemaSphere"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.06.003_bib0021","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"364","key":"10.1053\/j.seminhematol.2023.06.003_bib0022","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.06.003_bib0023","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"issue":"19","key":"10.1053\/j.seminhematol.2023.06.003_bib0024","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.06.003_bib0025","first-page":"3188","article-title":"Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders","volume":"5","author":"Stewart","year":"2021","journal-title":"Blood Adv"},{"issue":"34","key":"10.1053\/j.seminhematol.2023.06.003_bib0026","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal residual disease assessment in lymphoma: methods and applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.06.003_bib0027","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.06.003_bib0028","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.06.003_bib0029","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.06.003_bib0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Jim\u00e9nez-Ubieto","year":"2023","journal-title":"Leukemia"},{"issue":"20","key":"10.1053\/j.seminhematol.2023.06.003_bib0031","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198211113072002","article-title":"Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma","volume":"307","author":"Yunis","year":"1982","journal-title":"N Engl J Med"},{"issue":"4706","key":"10.1053\/j.seminhematol.2023.06.003_bib0032","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"issue":"7360","key":"10.1053\/j.seminhematol.2023.06.003_bib0033","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.06.003_bib0034","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"23","key":"10.1053\/j.seminhematol.2023.06.003_bib0035","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2023.06.003_bib0036","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.06.003_bib0037","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","article-title":"Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy","volume":"126","author":"Zohren","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.06.003_bib0038","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"14","key":"10.1053\/j.seminhematol.2023.06.003_bib0039","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1182\/bloodadvances.2020001955","article-title":"Lenalidomide\/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study","volume":"4","author":"Delfau-Larue","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.06.003_bib0040","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.06.003_bib0041","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2023.06.003_bib0042","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2023.06.003_bib0043","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","article-title":"Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study","volume":"128","author":"Pott","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.06.003_bib0044","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","article-title":"Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"101","author":"Luminari","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.06.003_bib0045","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","article-title":"MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial","volume":"34","author":"Pott","year":"2020","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.seminhematol.2023.06.003_bib0046","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9759","key":"10.1053\/j.seminhematol.2023.06.003_bib0047","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"23","key":"10.1053\/j.seminhematol.2023.06.003_bib0048","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM Study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.06.003_bib0049","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma","volume":"122","author":"Kridel","year":"2012","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1053\/j.seminhematol.2023.06.003_bib0050","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas","volume":"29","author":"Montoto","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.06.003_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.06.003_bib0052","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.06.003_bib0053","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/genes11070785","article-title":"Quantitative analysis and monitoring of EZH2 mutations using liquid biopsy in follicular lymphoma","volume":"11","author":"Nagy","year":"2020","journal-title":"Genes"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.06.003_bib0054","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2023.06.003_bib0055","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"10044","key":"10.1053\/j.seminhematol.2023.06.003_bib0056","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.06.003_bib0057","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with Mantle Cell Lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2023.06.003_bib0058","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2023.06.003_bib0059","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-140457","volume":"136","author":"Callanan","year":"2020","journal-title":"Blood."},{"issue":"13","key":"10.1053\/j.seminhematol.2023.06.003_bib0060","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.06.003_bib0061","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.06.003_bib0062","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.06.003_bib0063","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood.2021014270","article-title":"Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma","volume":"140","author":"Ferrero","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.06.003_bib0064","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.06.003_bib0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3324\/haematol.2016.147728","article-title":"Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome","volume":"102","author":"Minnema","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.06.003_bib0066","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/hon.2489","article-title":"The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid","volume":"36","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.06.003_bib0067","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjh.17703","article-title":"Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma","volume":"194","author":"Lyu","year":"2021","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1053\/j.seminhematol.2023.06.003_bib0068","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-Cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:29:21Z","timestamp":1758522561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0037196323000501"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.06.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical applications of circulating tumor DNA in indolent B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}